SHIRE PLC: Susan Kilsby to succeed Matthew Emmens as Chairman

Susan Kilsby to succeed Matthew Emmens as Chairman of Shire 
Dublin, Ireland - January 23, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) today
announces that Matthew Emmens will retire as Non-Executive Chairman and Susan
Kilsby, Chairman of Shire's Audit, Compliance & Risk Committee will succeed him
after the conclusion of Shire's AGM on 29 April 2014. 
Matt joined the company as Chief Executive in 2003 and became Chairman of Shire
in 2008. During his more than ten year tenure at Shire, the Company has grown
substantially, and now has a broad-based portfolio of products for specialist
and rare conditions marketed around the world as well as a diverse and valuable
pipeline of treatments in development. 
Susan Kilsby joined the Shire Board as a Non-Executive Director in September
2011 following a distinguished global career in investment banking. In May 2013
she was appointed Chairman of Shire's Audit, Compliance & Risk Committee. 
Upon becoming Chairman of the Board, Susan will step down as Chairman of
Shire's Audit, Compliance & Risk Committee. At that time, Dominic Blakemore
will become Chairman of that Committee. 
It is also announced that Susan will become a member of Shire's Nomination
Committee with effect from 1 February 2014. 
David Kappler, Deputy Chairman, Senior Independent Non-Executive Director and
Chairman of Shire's Nomination Committee said: 
"On behalf of all the Board, I would like to thank Matt Emmens for his many
contributions to Shire during the last decade. Susan will build on the strong
current Board dynamics and will make an excellent Chairman." 
Matthew Emmens, Shire Chairman commented: 
"I have thoroughly enjoyed my ten-plus years with Shire. The Company has
developed so much during this time and it continues to thrive and grow. Having
worked with Susan on the Board over the past few years I believe she is the
ideal Chairman for Shire as the Company embarks on another new era of growth." 
For further information please contact: 
Investor Relations                                                              
                                                                           
Eric Rojas                              erojas@shire.com     +1 781 482 0999    
                                                                           
Sarah Elton-Farr                        seltonfarr@shire.com +44 1256 894157    
                                                                           
Media                                                                           
                                                                           
Jessica Mann                            jmann@shire.com      +44 1256 894 280   
                                                                           
Gwen Fisher                             gfisher@shire.com    +1 484 595 9836    
NOTES TO EDITORS 
Susan is also a Non-Executive Director of BBA Aviation plc, Coca-Cola HBC AG
and Green Mountain Coffee Roasters Inc. Susan has served as a part-time Senior
Advisor to Credit Suisse Group AG since 2009 and this role will conclude when
she becomes Chairman. 
Earlier in her career, during her more than 30 years at Credit Suisse, she
served as Chairman of Mergers & Acquisitions, EMEA and Vice Chairman of the
European Investment Banking Committee, and also led the European Consumer,
Retail & Services Investment Banking Group. Her career in global investment
banking also includes senior positions with Barclays de Zoete Wedd, Bankers
Trust and The First Boston Corporation. 
She serves as the International Regional Chair of the Committee of 200 and was
a founding Member of the Competitor Diversity Forum. She is a Visiting Fellow
of the Cass Business School and is Chairman of the M&A Research Centre at Cass.
Susan also serves on the Advisory Board of the Yale School of Management and is
a Member of the Business Leadership Council of Wellesley College. 
An American national with UK citizenship, Susan gained her first degree in
Economics at Wellesley College and her MBA at Yale School of Management. She
has homes in the US and in Europe. 
About Shire 
Shire enables people with life-altering conditions to lead better lives. 
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs. 
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and
Internal Medicine and we are developing treatments for symptomatic conditions
treated by specialist physicians in other targeted therapeutic areas. 
www.shire.com 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX 
Press Release                                      
                                              
www.shire.com                                      
END 
-0- Jan/23/2014 07:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.